$LNTH News

Mizuho Downgrades Lantheus Holdings to Neutral, Lowers Price Target to $109

Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

Lantheus Receives Transitional Pass-Through Payment Status For PYLARIFY TruVu Injection From Centers For Medicare & Medicaid Services, Effective Oct. 1

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

Lantheus Holdings Announces First Patient Dosed In SPARROW NCT07831824, Phase 2/3 Registrational Trial Evaluating LNTH-2401

Lantheus Holdings (LNTH) Could Be 7% Undervalued On BRAVNETSA Approval

Lantheus Holdings (LNTH) Stock May Be 14% Undervalued On FDA Approval

Strong Earnings, FDA Approval, and Takeover Interest Drive Lantheus Holdings’ (LNTH) Rally

3 Reasons LNTH is Risky and 1 Stock to Buy Instead

Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for the Treatment of GEP-NETs

Curium acquisition of Lantheus backed by $5.375B of debt financing

Healthcare Equipment and Supplies Stocks Q2 Recap: Benchmarking Lantheus (NASDAQ:LNTH)

Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease

FDA Approves Lantheus Imaging Drug for Alzheimer's Diagnostics

Lantheus Holdings Announces FDA Approval Of TAUKLARIFY, Radiodiagnostic Agent Indicated For PET Of Brain In Adults For Alzheimer’s Disease

Lantheus Holdings: Why I Am Exiting Before The Merger Closes

Lantheus (NASDAQ:LNTH) Reports Upbeat Q2 CY2026

Lantheus Reports Second Quarter 2026 Financial Results

Lantheus Holdings Q2 Adj. EPS $1.55 Beats $1.30 Estimate, Sales $388.200M Beat $362.416M Estimate

Truist Securities Downgrades Lantheus Holdings to Hold, Lowers Price Target to $102.5